Literature DB >> 22895683

Association of dopaminergic/GABAergic genes with attention deficit hyperactivity disorder in children.

Guang-Xin Wang1, Yan-Hui Ma, Shi-Fu Wang, Guang-Fang Ren, Hui Guo.   

Abstract

Attention deficit hyperactivity disorder (ADHD) is the most commonly diagnosed neurobehavioral disorder in children and adolescents; however, its etiology is unknown. In this study, we investigated the association of five polymorphisms in dopaminergic/GABAergic genes with ADHD using polymerase chain reaction-restriction fragment length polymorphism in a group of 54 children with ADHD and 67 healthy controls. The distribution of AA genotype and A allele frequencies of rs5320 in the dopamine beta-hydroxylase gene in ADHD children differed significantly from that in healthy controls; however, no associations were found between four other polymorphisms in dopaminergic/GABAergic genes and ADHD. We also identified the best model consisting of four loci. We conclude that the rs5320 polymorphism may be considered as a genetic risk factor of ADHD, but the other four polymorphisms were not confirmed to be related directly to ADHD. The multilocus of dopaminergic/GABAergic genes acted in combination to affect susceptibility to ADHD in the children studied.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22895683     DOI: 10.3892/mmr.2012.1028

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  2 in total

1.  The dopamine beta-hydroxylase gene polymorphism rs1611114 is associated with schizophrenia in the Chinese Zhuang but not Chinese Han population.

Authors:  Jianxiong Long; Guifeng Huang; Baoyun Liang; Weijun Ling; Xiaojing Guo; Juan Jiang; Li Su
Journal:  Mol Genet Genomics       Date:  2016-05-28       Impact factor: 3.291

2.  Association between GABA3 Gene Polymorphisms and Attention Deficit Hyperactivity Disorder in Korean Children.

Authors:  Ho Jang Kwon; Wook Kim; Myung Ho Lim
Journal:  Psychiatry Investig       Date:  2017-09-11       Impact factor: 2.505

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.